ČESKÁ UROLOGIE / CZECH UROLOGY – 4 / 2021

243 Ces Urol 2021; 25(4): 236–243 PŘEHLEDOVÝ ČLÁNEK 35. Carlsson, SV, Vickers AJ, Lilja H, et al. Can one blood draw replace transrectal ultrasonography­ ‑estimated prostate volume to predict prostate cancer risk? BJU Int 2013; 112: 602–609 36. Catalona, WJ, Partin AW, Sanda MG, et al. A multicenter study of [-2]pro‑prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2 0 to 10 0 ng/ml prostate specific antigen range J Urol 2011; 185: 1650 37. Parekh, DJ, Punnen S Sjoberg DD, et al. A Multi‑institutional prospective trial in the USA confirms that the 4 K score accurately identifies men with high‑grade prostate cancer Eur Urol 2015; 68: 464–470 38. Nordstrom T, Vickers A, Assel M, et al. Comparison Between the Four‑kallikrein Panel and Prostate Health Index for Predicting Prostate Cancer Eur Urol 2015; 68: 139 39. NCCN Clinical Practice Guidelines in Oncology, 2017. Prostate Cancer Early Detection [online] 2018 [cit 2-4-2021] Dostupné z: wwwnccn org 40. Nordström T, Vickers A, Assel M, et al. Comparison Between the Four‑kallikrein Panel and Prostate Health Index for Predicting Prostate Cancer Eur Urol 2015; 68(1): 139-46 41. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function Cell 2004; 116(2): 281–297 42. Casanova‑Salas I, Rubio‑Briones J, Fernandez‑Serra A, Lopez‑Guerrero JA. miRNAs as biomarkers in prostate cancer Clin Transl Oncol 2012; 14(11): 803–811 43. Lawrie, CH, Gal S, Dunlop HM, et al. Detection of elevated levels of tumour‑associated microRNAs in serum of patients with diffuse large B‑cell lymphoma Br J Haematol 2008; 141: 672–675 44. Witwer KW. Circulating microRNA biomarker studies: Pitfalls and potential solutions Clin Chem 2015; 61: 56–63 45. Lucarelli G, Ditonno P, Bettocchi C, et al. Serum sarcosine is a risk factor for progression and survival in patients with metastatic castration‑resistant prostate cancer Future Oncol 2013; 9(6): 899–907 46. Ferro M, Lucarelli G, Bruzzese D, et al. Improving the prediction of pathologic outcomes in patients undergoing radical prostatectomy: the value of prostate cancer antigen 3 (PCA3), prostate health index (phi) and sarcosine Anticancer Res 2015; 35(2): 1017–1023 47. Mihelich BL, Maranville JC, Nolley R, et al. Elevated serummicroRNA levels associate with absence of high‑grade prostate cancer in a retrospective cohort PLoS ONE 2015; 10: e0124245 48. Fradet Y, Saad F, Aprikian A, et al. Upm3, a new molecular urine test for the detection of prostate cancer Urology 2004; 64: 311–315 49. Bettegowda C, Sausen M, Leary RJ, et al. Detection of circulating tumor DNA in early – and late‑stage human malignancies Sci Transl Med 2014; 6(224): 224ra24 50. de Bono JS, Scher HI, Montgomery RB, et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration‑resistant prostate cancer Clin Cancer Res 2008; 14: 6302–6309 51. Punnoose EA, Ferraldeschi R, Szafer-Glusman E, et al. Pten loss in circulating tumour cells correlates with pten loss in fresh tumour tissue from castration-resistant prostate cancer patients Br J Cancer 2015; 113: 1225–1233